Inflammation in ALS/FTD pathogenesis.

McCauley ME, Baloh RH. · 2019

Read Inflammation in ALS/FTD pathogenesis. by McCauley ME, Baloh RH. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6482122.txt.

Introduction

McCauley and Baloh review inflammation in ALS and frontotemporal dementia, twin diseases on one spectrum that kill motor neurons and personality respectively. ALS strikes 1.5 to 3 people per 100,000 yearly and kills within three to five years of symptoms. Inflamed glia appear in every end-stage brain, imaging and animal work place inflammation early, and patients carry signs of a body-wide autoinflammatory state.

Mutations in disease genes such as C9orf72, TBK1, and OPTN act directly inside immune cells, possibly setting the system's tone from birth. The puzzle the review circles: cooling microglia helps rodents, yet anti-inflammatory trials in humans have repeatedly failed to slow the disease.

Catalog record

CREATORMcCauley ME, Baloh RH.
YEAR2019
COLLECTIONPAPERS
FORMATTXT
FILE SIZE83 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC6482122

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Inflammation in ALS/FTD pathogenesis By Madelyn E. McCauley, Robert H. Baloh Published in: Acta Neuropathologica DOI: 10.1007/s00401-018-1933-9 ABSTRACT Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are neurodegenerative diseases that overlap in their clinical presentation, pathology and genetics, and likely represent a spectrum of one underlying disease. In ALS/FTD patients, neuroinflammation characterized by innate immune responses of tissue-resident glial cells is uniformly present on end-stage pathology, and human imaging studies and rodent models support that neuroinflammation begins early in disease pathogenesis. Additionally, changes in circulating immune cell populations and cytokines are found in ALS/FTD patients, and there is evidence for an autoinflammatory state. However, despite the prominent role of neuro- and systemic inflammation in ALS/FTD, and experimental evidence in rodents that altering microglial function can mitigate pathology, therapeutic approaches to decrease inflammation have thus far failed to alter disease course in humans. Here, we review the characteristics of inflammation in ALS/FTD in both the nervous and peripheral immune systems. We further discuss evidence for direct influence on immune cell function by mutations in ALS/FTD genes including C9orf72, TBK1 and OPTN, and how this could lead to the altered innate immune system “tone” observed in these patients. INTRODUCTION Amyotrophic lateral sclerosis (ALS) is a late-onset neurodegenerative disorder that primarily affects motor neurons. Loss of these neurons causes paralysis and death usually 3–5 years after symptom onset. The incidence of ALS in Europe and North America is reported to be between 1.5 and 3 per 100,000 people per year, with no treatments available that significantly alter disease course [65, 101]. Most cases of ALS are “sporadic” as they occur without a known cause or a family history. However, about 5–10% are caused by genetic mutations, typically passed down with dominant inheritance [22]. Neuropathological features include degeneration of motor neurons in the anterior horns of the spinal cord, brainstem, and large pyramidal neurons in the primary motor cortex. The death of motor neurons is accompanied by significant glial reaction, and ubiquitinated protein inclusions which typically contain the RNA-binding protein TDP-43. During the last few decades, many genes have been discovered that cause familial ALS or are over-represented in ALS patients compared to controls. These genes are involved in several cellular pathways, including RNA metabolism, protein homeostasis, and cytoskeletal dynamics, and provide researchers with tools to model ALS and study the molecular mechanisms underlying the disease. While all these genes are expressed in a variety of non-neuronal cells, including cells of the immune system, the majority of research has focused on their role in neurons, as they are the cells that ultimately degenerate in ALS. ALS shares significant overlap with another fatal neurodegenerative disease, frontotemporal dementia (FTD) [111]. FTD is characterized by degeneration of the frontal and temporal lobes, and is associated with behavioral and personality changes, and impairment in social interactions. Approximately, 15% of patients with FTD develop motor neuron dysfunction, and up to 50% of patients with ALS develop frontal lobe dysfunction [88]. Pathologically, ALS and FTD are thought to be at different ends of a spectrum, with the presence of ubiquitinated neuronal cytoplasmic inclusions positive for TDP-43 found in both diseases. The two also share common genetic origins, with a mutation in C9orf72 being the most common cause [158]. Hexanucleotide repeat expansions in C9orf72 have been identified in up to 40% of familial ALS patients, and 20% of familial FTD patients, in addition to around 6% of sporadic ALS and FTD patients [34, 128]. Multiple other genes, such as VCP, FUS and TARDBP have also been linked to both diseases, and in each case members of a family can manifest either ALS, FTD, or both [77, 78, 84, 142, 154]. However, while the clinical, genetic and pathologic overlaps are well defined, the reasons why individual patients manifest different parts of the ALS/FTD spectrum remains a mystery. Neuroinflammation is a term that broadly describes the reaction of resident glial cells (astrocytes, microglia) and circulating immune cells (monocytes, neutrophils, lymphocytes) that enter and interact with cells of the CNS in the context of infection, injury or degeneration. Neuroinflammation in ALS, as in other neurodegenerative diseases, is characterized primarily by an innate immune response rather than an adaptive immune response [126]. However, while astrocyte and microglial activation are the most prominent features on pathology, autopsy tissue from ALS patients also displays T cells [38, 79, 167], and non-resident innate immune cells (dendritic cells, macrophages, mast cells) [59, 68, 70]. The role of these other immune cells in disease pathogenesis remains poorly understood. In addition to neuroinflammation, there is also evidence for systemic inflammation in ALS, as altered circulating lymphocyte and monocyte populations have been reported [107, 166], as well as inflammatory cytokines and other immune markers [99]. However, while neuroinflammation and systemic inflammation are uniformly present in ALS patients, it is still debated whether these phenomena are simply a consequence of disease, or instead play a contributory or even causative role. In this review, we focus on the role of immune cells in ALS pathogenesis, discuss how their dysfunction influences neuroinflammation and systemic inflammation, and could contribute to disease risk or progression. In particular, we focus on a group of ALS genes including C9orf72, TBK1, and OPTN that have well-characterized roles regulating innate immune cell function. We discuss how mutations in these genes could alter innate immune “tone” in ALS patients, through their effect on myeloid-derived innate immune cell populations in the brain and the periphery. Diversity of myeloid populations that influence neuroinflammation Myeloid cells are generally defined as those resulting from a myeloblast lineage, and include neutrophils, basophils, eosinophils, monocytes/macrophages and dendritic cells [48]. They originate from hematopoietic cells in the bone marrow and are constantly distributed throughout the body. They play a key role in the innate immune response, producing cytokines and chemokines to mitigate infection, activating the adaptive immune system through antigen presentation, and maintaining tissue homeostasis [48]. In the CNS parenchyma, microglia are the primary myeloid cell type, making up 5–15% of cells in the brain [91, 119] and are responsible for development, immune surveillance, and tissue homeostasis [83, 96, 134, 149]. During steady state, these cells are constantly surveying their environment, and upon injury microglia migrate to the damaged areas and produce cytokines and neurotrophic factors to mitigate damage [83]. Through phagocytosis, microglia engage in the clearance of pathogens and debris, as well as synaptic elements during development and likely disease [72]. As a stereotyped response to a pro-inflammatory environment, microglia also change their morphology and upregulate Iba1, CD11b and antigen presentation molecules (CD80/CD86) in response to pathogens or infection [89]. Microglia are unique among tissue macrophages in that they are a self-renewing population derived from early yolk-sac precursors, and are not replaced or expanded by circulating macrophages except in the case of tissue injury [2, 16, 55]. Under homeostatic conditions, there are few if any infiltrating myeloid cells in the CNS; however, breakdown of the blood–brain barrier in many disease states can lead to infiltration of monocyte-derived macrophages that are phenotypically different from resident microglia, but similarly work to alleviate damage caused by an insult [1, 62, 109, 123]. Microglia are extremely sensitive to changes in their environment and are known to react to danger signals present both

Read the complete text